| Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Immunovant (IMVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-02-12 12:36:22 |
Czytaj oryginał (ang.) |
| IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus |
Immunovant stock down on dismal third-quarter fiscal 2025 results. It is on track to initiate 10 studies on IMVT-1402 across various autoimmune indications. |
zacks.com |
2025-02-07 13:10:20 |
Czytaj oryginał (ang.) |
| Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 |
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024. |
globenewswire.com |
2025-02-06 08:30:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm |
NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. |
prnewswire.com |
2025-01-24 15:34:00 |
Czytaj oryginał (ang.) |
| A Huge Biotech Purchase Highlights New Year's Insider Buying |
The year started off slow as far as insider purchases go. |
247wallst.com |
2025-01-19 11:15:30 |
Czytaj oryginał (ang.) |
| Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study |
Immunovant aims to initiate a pivotal registration study for IMVT-1402 targeting Graves' Disease by the end of 2024, with 4–5 trials in other IgG-mediated autoimmune disorders by March 2025. IMVT-1402 offers deeper IgG suppression without increasing LDL cholesterol like Batoclimab does. Financial caution is advised as Immunovant's cash runway only extends for 12 months, likely necessitating IMVT to make a cash raise in 2025. |
seekingalpha.com |
2024-12-27 12:50:09 |
Czytaj oryginał (ang.) |
| FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial |
Presents Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, and FcRn Inhibitor Market Size from 2020 to 2034 Presents Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, and FcRn Inhibitor Market Size from 2020 to 2034 |
globenewswire.com |
2024-12-11 08:25:00 |
Czytaj oryginał (ang.) |
| Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus |
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications. |
zacks.com |
2024-11-08 13:41:12 |
Czytaj oryginał (ang.) |
| Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 |
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported development updates and financial results for its fiscal second quarter ended September 30, 2024. |
globenewswire.com |
2024-11-07 08:30:00 |
Czytaj oryginał (ang.) |
| Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting |
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves' disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting both thyroid-specific and extrathyroidal manifestations of Graves' disease will be presented. |
globenewswire.com |
2024-10-29 08:30:00 |
Czytaj oryginał (ang.) |
| What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday? |
Monday, Immunovant, Inc. IMVT reported results from the Phase 2a trial of batoclimab in Graves' Disease, an immune system condition that affects the thyroid gland. It causes the body to make too much thyroid hormone. |
benzinga.com |
2024-09-09 16:54:13 |
Czytaj oryginał (ang.) |
| IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab |
Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy options. |
zacks.com |
2024-09-09 13:35:17 |
Czytaj oryginał (ang.) |
| Top 2 Health Care Stocks That May Collapse This Quarter |
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. |
benzinga.com |
2024-09-09 13:12:44 |
Czytaj oryginał (ang.) |
| Roivant Provides Update on Graves' Disease Development Program |
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food & Drug Administration (FDA) and Investigational New Drug Application (IND) clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024. |
globenewswire.com |
2024-09-09 11:00:00 |
Czytaj oryginał (ang.) |
| Immunovant Provides Update on Graves' Disease Development Program |
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food & Drug Administration (FDA) and Investigational New Drug Application (IND) clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024. |
globenewswire.com |
2024-09-09 07:55:00 |
Czytaj oryginał (ang.) |
| Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report? |
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-05 16:36:11 |
Czytaj oryginał (ang.) |
| Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging |
In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 2000 remains a more appropriate benchmark for comparison. Top gainers include FTAI Aviation and FTAI Infrastructure, while top detractors include Latch and Industrial Short. |
seekingalpha.com |
2024-08-06 12:25:00 |
Czytaj oryginał (ang.) |
| Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus |
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications. |
zacks.com |
2024-05-30 16:31:10 |
Czytaj oryginał (ang.) |
| Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 |
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024. |
globenewswire.com |
2024-05-29 20:01:00 |
Czytaj oryginał (ang.) |
| Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump |
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations. |
investors.com |
2024-05-29 13:12:14 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-05-13 14:55:20 |
Czytaj oryginał (ang.) |
| 5 Biotech Stocks Worth Adding to Your Portfolio in 2024 |
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility. |
zacks.com |
2024-05-06 14:51:04 |
Czytaj oryginał (ang.) |
| Here's Why You Should Add Immunovant (IMVT) to Your Portfolio |
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025. |
zacks.com |
2024-04-22 16:56:07 |
Czytaj oryginał (ang.) |
| What Makes Immunovant (IMVT) a New Buy Stock |
Immunovant (IMVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-04-17 17:01:06 |
Czytaj oryginał (ang.) |